• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Favorable outcomes and the association between dynamic transfusion dependence and IPSS-M in MDS-h and MDS-LB patients undergoing allo-HSCT.

作者信息

Guo Wenjing, Li Jia, Wang Hui, Fan Yuping, Zhang Tingting, Cao Yigeng, Cao Wenbin, Pang Aiming, Yang Donglin, Chen Xin, Zhang Rongli, Wei Jialin, Ma Qiaoling, Zhai Weihua, He Yi, Zheng Yizhou, Jiang Erlie, Han Mingzhe, Feng Sizhou

机构信息

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.

Tianjin Institutes of Health Science, Tianjin, China.

出版信息

Bone Marrow Transplant. 2025 Apr 25. doi: 10.1038/s41409-025-02613-2.

DOI:10.1038/s41409-025-02613-2
PMID:40281207
Abstract
摘要

相似文献

1
Favorable outcomes and the association between dynamic transfusion dependence and IPSS-M in MDS-h and MDS-LB patients undergoing allo-HSCT.接受异基因造血干细胞移植的骨髓增生异常综合征-低危组（MDS-h）和低原始细胞比例骨髓增生异常综合征（MDS-LB）患者的良好预后以及动态输血依赖与国际预后评分系统-骨髓（IPSS-M）之间的关联。
Bone Marrow Transplant. 2025 Apr 25. doi: 10.1038/s41409-025-02613-2.
2
Threefold IPSS-M reclassification outperforms original stratification in predicting post-transplant outcomes for MDS patients.在预测骨髓增生异常综合征（MDS）患者移植后结局方面，IPSS-M三分法重新分类优于原始分层。
Cell Transplant. 2025 Jan-Dec;34:9636897251348406. doi: 10.1177/09636897251348406. Epub 2025 Jun 24.
3
IPSS-M risk and specific sex-associated somatic mutations predict response to ESA therapy in LR-MDS: building a new score.国际预后评分系统-骨髓增生异常综合征（IPSS-M）风险及特定性别相关体细胞突变可预测低危骨髓增生异常综合征（LR-MDS）患者对促红细胞生成素（ESA）治疗的反应：构建新的评分系统
Blood. 2025 Jun 25. doi: 10.1182/blood.2024027540.
4
[Relationship between Peripheral Blood TIM-3 and Iron Overload in Patients with Myelodysplastic Syndrome Undergoing Red Blood Cell Transfusion].[接受红细胞输血的骨髓增生异常综合征患者外周血TIM-3与铁过载的关系]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2025 Jun;33(3):841-847. doi: 10.19746/j.cnki.issn.1009-2137.2025.03.032.
5
[Analysis of the association between pre- and post-treatment genetic mutation status and treatment efficacy and survival in patients with newly diagnosed myelodysplastic syndromes with excess blasts receiving hypomethylating agent therapy].[新诊断的伴过多原始细胞的骨髓增生异常综合征患者接受去甲基化药物治疗前后基因突变状态与治疗疗效及生存的相关性分析]
Zhonghua Xue Ye Xue Za Zhi. 2025 May 14;46(5):417-424. doi: 10.3760/cma.j.cn121090-20241210-00553.
6
Long-Term Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: An Italian Multicenter Collaborative Study.复发/难治性B细胞非霍奇金淋巴瘤异基因造血干细胞移植后的长期结局：一项意大利多中心协作研究
Transplant Cell Ther. 2025 Jun 18. doi: 10.1016/j.jtct.2025.06.004.
7
Prospective performance of the IWG-2023 criteria and IPSS-M in a phase 2 trial of guadecitabine for higher-risk MDS or CMML.在一项关于地西他滨治疗高危骨髓增生异常综合征或慢性粒-单核细胞白血病的2期试验中，IWG-2023标准和IPSS-M的前瞻性表现。
Blood Neoplasia. 2024 Mar 29;1(2):100008. doi: 10.1016/j.bneo.2024.100008. eCollection 2024 Jun.
8
[Clinical Efficacy of the MDS Patients Treated by Allo-HSCT].[异基因造血干细胞移植治疗骨髓增生异常综合征患者的临床疗效]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021 Feb;29(1):172-180. doi: 10.19746/j.cnki.issn.1009-2137.2021.01.027.
9
Allogenic hematopoietic stem cell transplantation outcomes of patients aged ≥ 55 years with acute myeloid leukemia or myelodysplastic syndromes in China: a retrospective study.中国≥55 岁急性髓系白血病或骨髓增生异常综合征患者异基因造血干细胞移植的结果：一项回顾性研究。
Stem Cell Res Ther. 2024 Jan 29;15(1):24. doi: 10.1186/s13287-024-03640-4.
10
Red blood cell transfusion in myelodysplastic syndromes: A systematic review.骨髓增生异常综合征的红细胞输注：系统评价。
Transfus Med. 2022 Feb;32(1):3-23. doi: 10.1111/tme.12841. Epub 2021 Dec 19.

本文引用的文献

1
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes.基于临床和基因组的决策支持系统，以确定骨髓增生异常综合征患者异基因造血干细胞移植的最佳时机。
J Clin Oncol. 2024 Aug 20;42(24):2873-2886. doi: 10.1200/JCO.23.02175. Epub 2024 May 9.
2
Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes.早期输血模式可改善骨髓增生异常综合征的分子国际预后评分系统（IPSS-M）预测。
J Intern Med. 2024 Jul;296(1):53-67. doi: 10.1111/joim.13790. Epub 2024 Apr 23.
3
The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms.
2022 年 WHO 和 ICC 髓系肿瘤分类系统的临床、分子和预后特征。
Leuk Res. 2024 Jan;136:107433. doi: 10.1016/j.leukres.2023.107433. Epub 2023 Dec 19.
4
Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes.评估和验证骨髓增生异常综合征的分子国际预后评分系统。
Leukemia. 2023 Jul;37(7):1530-1539. doi: 10.1038/s41375-023-01910-3. Epub 2023 May 5.
5
Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms.比较修订版第 4 版（2016 年）和第 5 版（2022 年）世界卫生组织骨髓增生异常肿瘤分类。
Leukemia. 2022 Dec;36(12):2875-2882. doi: 10.1038/s41375-022-01718-7. Epub 2022 Oct 12.
6
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.世界卫生组织血液淋巴肿瘤分类第五版：髓系和组织细胞/树突状肿瘤。
Leukemia. 2022 Jul;36(7):1703-1719. doi: 10.1038/s41375-022-01613-1. Epub 2022 Jun 22.
7
Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome.基于供者可用性的 50-75 岁中高危骨髓增生异常综合征患者减低强度异基因造血干细胞移植的生物学分配试验
J Clin Oncol. 2021 Oct 20;39(30):3328-3339. doi: 10.1200/JCO.20.03380. Epub 2021 Jun 9.
8
Comparison of transfusion requirements in adult patients undergoing Haploidentical or single-unit umbilical cord blood stem cell transplantation.成人患者接受单倍体相合或单份脐带血造血干细胞移植的输血需求比较。
Eur J Haematol. 2019 Sep;103(3):172-177. doi: 10.1111/ejh.13270. Epub 2019 Jul 3.
9
A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation.一项关于输血负担和相关铁毒性对接受异基因造血细胞移植的骨髓增生异常综合征患者结局影响的前瞻性非干预性研究。
Leuk Lymphoma. 2019 Oct;60(10):2404-2414. doi: 10.1080/10428194.2019.1594215. Epub 2019 Apr 18.